ANDA 62334, held by Apothecon. Cefadroxil/Cefadroxil Hemihydrate.
As of Nov 15, 2026, ANDA 62334 (Cefadroxil), held by Apothecon, was not approved, with 0 approved supplements and 0 published complete response letters.
| CefadroxilEQ 125MG BASE/5ML · for suspension;oral | Cefadroxil/Cefadroxil Hemihydrate | Discontinued |
| CefadroxilEQ 250MG BASE/5ML · for suspension;oral | Cefadroxil/Cefadroxil Hemihydrate | Discontinued |
| CefadroxilEQ 500MG BASE/5ML · for suspension;oral | Cefadroxil/Cefadroxil Hemihydrate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters